KPIs & Operating Metrics(New)
Breakdown Of AssetsContractual ObligationsCvaccines Revenue BreakdownDeferred RevenueEbt By SegmentEbt Margin By Segment %Employee StatisticsGross Margin %Gross ProfitGross Profit AnnualGross Profit Annual %Hospital Revenue BreakdownIncome Before Income TaxInflammation And Immunology Revenue BreakdownInternal Medicine Revenue BreakdownInventoriesLong Lived Assets By RegionNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Oncology Revenue BreakdownOperating Costs & ExpensesOpex & Costs As A % Of RevenueProperty, Plant And Equipment SegregationRare Disease Revenue BreakdownRemaining Performance ObligationsRemaining Performance Obligations AnnualRevenue By Business VerticalRevenue By Business Vertical %Revenue By Business Vertical Annual %Revenue By Customer GroupRevenue By Customer Group %Revenue By Products AnnualaRevenue By Products Annuala %Revenue By RegionRevenue By Region %Revenue By Region AnnualRevenue By Region Annual %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %Revenue By Therapeutic Area AnnualRevenue By Therapeutic Area Annual %Revenue By WholesalersRevenue By Wholesalers %U.S Revenue By Wholesalers %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) Gross Profit (2019 - 2024)

Pfizer (PFE) has disclosed Gross Profit for 17 consecutive years, with $12.3 billion as the latest value for Q4 2025.

  • Quarterly Gross Profit changed N/A to $12.3 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $32.2 billion through Dec 2025, changed N/A year-over-year, with the annual reading at $46.5 billion for FY2025, 591.51% up from the prior year.
  • Gross Profit for Q4 2025 was $12.3 billion at Pfizer, up from -$1.9 billion in the prior quarter.
  • The five-year high for Gross Profit was $19.1 billion in Q3 2022, with the low at -$4.8 billion in Q3 2024.
  • Average Gross Profit over 5 years is $8.0 billion, with a median of $10.9 billion recorded in 2025.
  • Peak annual rise in Gross Profit hit 3845.85% in 2024, while the deepest fall reached 214.19% in 2024.
  • Over 5 years, Gross Profit stood at $14.1 billion in 2021, then increased by 17.53% to $16.6 billion in 2022, then crashed by 124.91% to -$4.1 billion in 2023, then dropped by 16.76% to -$4.8 billion in 2024, then soared by 354.82% to $12.3 billion in 2025.
  • According to Business Quant data, Gross Profit over the past three periods came in at $12.3 billion, -$1.9 billion, and $10.9 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.